Coherus Biosciences, Inc. (CHRS): Peter K. Watler , Chief Technical Officer of Coherus Biosciences, Inc. sold 43,495 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $20.02 per share for a total value of $870,930.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, Alan C. Herman (Chief Scientific Officer) sold 4,250 shares at $16.89 per share price.On May 26, 2016, Mats Wahlstrom (director) sold 6,372 shares at $33.50 per share price.Also, On May 19, 2016, Peter K. Watler (Chief Technical Officer) sold 12,000 shares at $20.00 per share price.On Dec 2, 2015, Dennis M Lanfear (President and CEO) sold 400 shares at $31.75 per share price.
Coherus Biosciences Inc: On Monday, Jul 11, 2016 heightened volatility was witnessed in Coherus Biosciences Inc which led to swings in the share price. The shares opened for trading at $17.88 and hit $22 on the upside , eventually ending the session at $21.93, with a gain of 27.35% or 4.71 points. The heightened volatility saw the trading volume jump to 18,61,184 shares. The 52-week high of the share price is $38.1 and the company has a market cap of $858 M . The 52-week low of the share price is at $12.04.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.